Evidence map›Paper›PMID 21586552›Full record

ArticleEndocrinology2011

Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

Jaime Kulak, Catha Fischer, Barry Komm, Hugh S Taylor

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. The prospects of cell therapy for endometriosis.Journal of assisted reproduction and genetics · 2023
    Review
  11. Article
  12. Review
  13. Review
  14. Hormonal treatments for endometriosis: The endocrine background.Reviews in endocrine & metabolic disorders · 2022
    Review
  15. Review
  16. Review
  17. Management Challenges of Deep Infiltrating Endometriosis.International journal of fertility & sterility · 2021
    Review
  18. Review
  19. Article
  20. Estrogen Receptors and Endometriosis.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jaime KulakDivision of Reproductive Endocrinology and Infertility, Yale University, 333 Cedar Street, New Haven, Connecticut 06510, USA.
Catha Fischer
Barry Komm
Hugh S Taylor
Yale University · USPfizer (United States) · US

Funding

Tissue Factor and EmdometriosisU54HD052668 · NICHD · YALE UNIVERSITY · PI OSTEEN, KEVIN G · 2007 to 2011
$6.6M
NICHD NIH HHS U54 HD052668NICHD NIH HHS U54HD052668
6 · The paper itself

Abstract

Endometriosis is a common estrogen-dependent disorder. Medical treatments currently consist of progestins or GnRH agonists; however, neither is fully effective and both entail significant side effects. Selective estrogen receptor (ER) modulators (SERM) have tissue-selective actions, acting as an ER agonist in some tissues and ER antagonist in others. The SERM bazedoxifene (BZA) effectively antagonizes estrogen-induced uterine endometrial stimulation without countering estrogenic effects in bone or central nervous system. These properties make it an attractive candidate for use in the treatment of endometriosis. Experimental endometriosis was created in reproductive-age CD-1 mice. After 8 wk, 10 animals received i.p. injections of BZA (3 mg/kg·d) for 8 wk, whereas 10 received vehicle control. Mice were killed, and implant size was assessed. The mean size of the implants after treatment was 60 mm(2) in the control group and 21 mm(2) in the BZA treatment group (P = 0.03). Quantitative PCR and immunohistochemical analysis were used to determine the effect on endometrial gene expression. PCNA, ERα, and LIF mRNA and protein expression were significantly decreased in endometrium of the treated group. Caspase 3 mRNA expression was increased. Expression of PR and Hoxa10 were not significantly altered by treatment. There was no evidence of ovarian enlargement or cyst formation. Decreased PCNA and ER expression demonstrated that the regression of endometriosis likely involved decreased estrogen-mediated cell proliferation. BZA may be an effective novel agent for the treatment of endometriosis due to greater endometrial-specific estrogen antagonism compared with other SERM.

Indexed as

AnimalsCaspase 3Disease Models, AnimalEndometriosisFemaleIndolesMiceProliferating Cell Nuclear AntigenReceptors, EstrogenSelective Estrogen Receptor ModulatorsbazedoxifeneCaspase 3IndolesProliferating Cell Nuclear AntigenReceptors, EstrogenSelective Estrogen Receptor Modulators

Identifiers

PMID21586552
PMCPMC3138238
OpenAlexW2152300718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.